Find a Cancer Provider

Are you a referring physician?
I am searching for a
Brian J. Czerniecki, MD, PhD

Brian J. Czerniecki, MD, PhD Physician

Co-Director, Rena Rowan Breast Center
Rhoads-Harrington Professor in Surgery

Dr. Czerniecki is a Penn Medicine employed physician.

About Dr. Brian J. Czerniecki

Recognized in Philadelphia Magazine's 2012 - 2015 Top Docs issue

Recognized by America's Top Doctors, 2013-4

Recognized by Best Doctors in America 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014

Clinical Specialties


  • Surgery
    • Endocrine and Oncologic Surgery

Programs & Centers:

  • Cancer
    • Breast Cancer Program

Board Certification:

  • Surgery, 1994

Clinical Expertise:

  • Breast Cancer
  • breast surgery - non-cosmetic
  • Colon Cancer
  • Ductal Carcinoma in Situ (DCIS)
  • Inflammatory Breast Cancer (IBC)
  • Invasive (Infiltrating) Ductal Carcinoma (IDC)
  • Invasive (Infiltrating) Lobular Carcinoma (ILC)
  • Male Breast Cancer
  • Melanoma
  • Other types of Breast Cancer
  • Sarcoma
  • Triple-Negative Breast Cancer

Practice Locations and Appointments

  • Rena Rowan Breast Center

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 3rd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

  • Endocrine and Oncologic Surgery

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Medicine and Dentistry of New Jersey
Residency: Ohio State University Hospital
Fellowship: National Cancer Institute


ACS IRG for the Abramson Cancer Center, Local Ad hoc Reviewer NIH SRG Cancer Immunology Immunopathology Study Section, National American Association for Cancer Research, American College of Surgeons, American College of Surgeons, American Society Clinical Oncology, American Society of Breast Diseases, NIH Ad-Hoc Reviewer Clinical Oncology Study Section D, National Philadelphia Chapter, Robert M. Zollinger Society, Society of Biologic Therapy, Society of Surgical Oncology,

Hospital Affiliation

Dr. Czerniecki is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Selected Publications:

Choe, R, Konecky SD, Corlu A, Lee K, Durduran T, Busch DR, Pathak S, Czerniecki BJ, Tchou J, Fraker DL, DeMichele A, Chance B, Arridge SR, Schweiger M, Culver JP, Schnall MD, Putt ME, Rosen MA,Yodh AG.: Differentiation of benign and malignant breast tumors by in vivo three dimensional parallel-plate diffuse optical tomography. Journal of Biomedical Optics. 14 : 2009.

Bahl S, Roses R, Sharma, A, Koldovsky U, Xu S, Weinstein S, Nisenbaum H, Fox K, Pasha T, Zhang P, Araujo L, Carver J, Czerniecki BJ.: Asymptomatic changes in cardiac function can occur in DCIS patients following treatment with HER-2/neu pulsed dendritic cell vaccines. Am Journal Surgery. : 2009.

Roses RE, Paulson C, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, Fox KR, Zhang PJ, Czerniecki BJ.: HER-2/neu over-expression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiology, Biomarkers and Prevention. 18 : 1386-1389,2009.

Roses R, Xu M, Koski GK, Czerniecki BJ.: Radiation therapy and toll-like receptor signaling: implications for the treatment of cancer. Oncogene. 27 : 200-207,2008.

Sharma A, Czerniecki BJ.: Utilizing Genetic Phenotypes and Cancer Stem Cells as Novel Targets for Breast Cancer Vaccine Development. Current Medical Literature Breast Cancer. 20 (3): 61-67,2008.

Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Barbiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN.: Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clinical Oncology. 27 : 1-10,2008.

Koski GK, Roses R, Xu S, Cohen PA, Czerniecki BJ.: Re-engineering dendritic cell-based anti-cancer vaccines. Immunologic Reviews. 222 : 256-276,2008.

Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ.: Differential production of interleukin-23 and interleukin-12 by myeloid derived dendritic cells in response to toll-like receptor agonists. J Immunol. 181 : 5120-5127,2008.

Tchou J, Greshock J, Bergey M, Sonnad SS, Sargen M, Weinstein S, Czerniecki B, Boraas M, Fraker DL, Rosato E, Fox K, Weber B, Solin LJ.: Method of primary tumor detection as a risk factor for local and distant recurrence after breast conservation treatment for early stage breast cancer. Clinical Breast Cancer. 8 : 2,2008.

Cohen PA, Koski GK, Czerniecki BJ, Bunting K, Fu XY, Wang Z, Zhang WJ, Carter C, Awad M, Distel CA, Hassen N, Paustian C, Johnson T, Tisdale JF, Shu S.: STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34 positive cells into tumor-competent dendritic cells. Blood. 112 : 1832-1843,2008.

Academic Contact Info

Department of Surgery
Division of Surgical Oncology
Hospital of the University of Pennsylvania
3400 Civic Center Drive, 3 Perelman Center

Philadelphia, PA 19104
Phone: (215) 662-4392
Patient appointments: 800-789-PENN (7366)

Related Links